Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Fina Climent

Showing results (71-80 of 82) with videos related to

Pageof 9
Sort By:
Hemasphere|October 9, 2024
Testicular large B-cell lymphoma is genetically similar to PCNSL and distinct from nodal DLBCLAlfredo Rivas-Delgado, Cristina López, Guillem Clot, et al.
Blood Cancer Journal|September 23, 2024
Large B-cell lymphomas with CCND1 rearrangement have different immunoglobulin gene breakpoints and genomic profile than mantle cell lymphomaEce Özoğul, Anna Montaner, Melina Pol, et al.
Breast Cancer Research and Treatment|May 5, 2011
Evidence for a link between TNFRSF11A and risk of breast cancerNúria Bonifaci, Marta Palafox, Pasquale Pellegrini, et al.
Blood|December 13, 2018
<i>CCND2</i> and <i>CCND3</i> hijack immunoglobulin light-chain enhancers in cyclin D1<sup>-</sup> mantle cell lymphomaDavid Martín-Garcia, Alba Navarro, Rafael Valdés-Mas, et al.
Plos One|November 13, 2018
Correction: Lymphangioleiomyomatosis Biomarkers Linked to Lung Metastatic Potential and Cell StemnessGorka Ruiz de Garibay, Carmen Herranz, Alicia Llorente, et al.
Plos One|July 14, 2015
Lymphangioleiomyomatosis Biomarkers Linked to Lung Metastatic Potential and Cell StemnessGorka Ruiz de Garibay, Carmen Herranz, Alicia Llorente, et al.
Ejhaem|September 2, 2022
An integrated prognostic model for diffuse large B-cell lymphoma treated with immunochemotherapyMarta Rodríguez, Ruth Alonso-Alonso, Ismael Fernández-Miranda, et al.
The British Journal of Dermatology|August 12, 2025
EORTC/USCLC/ISCL consensus recommendations for management and treatment of cutaneous lymphoproliferative disordersRein Willemze, Chalid Assaf, Martine Bagot, et al.
Nature Communications|September 1, 2021
Molecular and functional profiling identifies therapeutically targetable vulnerabilities in plasmablastic lymphomaFabian Frontzek, Annette M Staiger, Myroslav Zapukhlyak, et al.
Breast Cancer Research : BCR|June 3, 2014
VAV3 mediates resistance to breast cancer endocrine therapyHelena Aguilar, Ander Urruticoechea, Pasi Halonen, et al.
Pageof 9

Showing results (71-80 of 82) with videos related to

Sort By:
Pageof 9
Hemasphere|October 9, 2024
Testicular large B-cell lymphoma is genetically similar to PCNSL and distinct from nodal DLBCLAlfredo Rivas-Delgado, Cristina López, Guillem Clot, et al.
Blood Cancer Journal|September 23, 2024
Large B-cell lymphomas with CCND1 rearrangement have different immunoglobulin gene breakpoints and genomic profile than mantle cell lymphomaEce Özoğul, Anna Montaner, Melina Pol, et al.
Breast Cancer Research and Treatment|May 5, 2011
Evidence for a link between TNFRSF11A and risk of breast cancerNúria Bonifaci, Marta Palafox, Pasquale Pellegrini, et al.
Blood|December 13, 2018
<i>CCND2</i> and <i>CCND3</i> hijack immunoglobulin light-chain enhancers in cyclin D1<sup>-</sup> mantle cell lymphomaDavid Martín-Garcia, Alba Navarro, Rafael Valdés-Mas, et al.
Plos One|November 13, 2018
Correction: Lymphangioleiomyomatosis Biomarkers Linked to Lung Metastatic Potential and Cell StemnessGorka Ruiz de Garibay, Carmen Herranz, Alicia Llorente, et al.
Plos One|July 14, 2015
Lymphangioleiomyomatosis Biomarkers Linked to Lung Metastatic Potential and Cell StemnessGorka Ruiz de Garibay, Carmen Herranz, Alicia Llorente, et al.
Ejhaem|September 2, 2022
An integrated prognostic model for diffuse large B-cell lymphoma treated with immunochemotherapyMarta Rodríguez, Ruth Alonso-Alonso, Ismael Fernández-Miranda, et al.
The British Journal of Dermatology|August 12, 2025
EORTC/USCLC/ISCL consensus recommendations for management and treatment of cutaneous lymphoproliferative disordersRein Willemze, Chalid Assaf, Martine Bagot, et al.
Nature Communications|September 1, 2021
Molecular and functional profiling identifies therapeutically targetable vulnerabilities in plasmablastic lymphomaFabian Frontzek, Annette M Staiger, Myroslav Zapukhlyak, et al.
Breast Cancer Research : BCR|June 3, 2014
VAV3 mediates resistance to breast cancer endocrine therapyHelena Aguilar, Ander Urruticoechea, Pasi Halonen, et al.
Pageof 9